New Prospects on the NKG2D/NKG2DL System for Oncology

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2013 Dec 20

PMID 24353908

Citations 76

Authors

Evelyn Ullrich

Joachim Koch

Adelheid Cerwenka

Alexander Steinle

Affiliations

Soon will be listed here.

Abstract

The activating immunoreceptor NKG2D endows cytotoxic lymphocytes with the capacity to recognize and eliminate infected or malignant cells. The recognition of such harmful cells is enabled by binding of NKG2D to various MHC class I-related glycoproteins, which are upregulated in the course of viral infection or malignant transformation. The past years have witnessed substantial progress in our understanding of the mechanisms underlying the regulation of NKG2D ligands (NKG2DLs) by malignant cells, of tumor-associated countermeasures promoting escape from NKG2D-dependent immunosurveillance, and of therapeutic measures that may bolster the NKG2D/NKG2DL system against malignancies. Here, we summarize the current knowledge on the NKG2D/NKG2DL system and outline opportunities to exploit the tumoricidal function of NKG2D for anticancer immunotherapy.

Citing Articles

Resveratrol contributes to NK cell-mediated breast cancer cytotoxicity by upregulating ULBP2 through miR-17-5p downmodulation and activation of MINK1/JNK/c-Jun signaling.

Ding B, Li J, Yan J, Jiang C, Qian L, Pan J Front Immunol. 2025; 16:1515605.

PMID: 39963142 PMC: 11830804. DOI: 10.3389/fimmu.2025.1515605.

Natural killer cell engagers: From bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy.

Zhu A, Bai Y, Nan Y, Ju D Clin Transl Med. 2024; 14(11):e70046.

PMID: 39472273 PMC: 11521791. DOI: 10.1002/ctm2.70046.

Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia.

Leifheit M, Johnson G, Kuzel T, Schneider J, Barker E, Yun H Int J Mol Sci. 2024; 25(17).

PMID: 39273395 PMC: 11394928. DOI: 10.3390/ijms25179448.

More balance toward activating receptors and cytotoxic activity of NK cells ex vivo differentiated from human umbilical cord blood-derived CD34 stem cells in comparison with peripheral blood NK cells.

Ghaedrahmati F, Esmaeil N, Akbari V, Ashrafi F Heliyon. 2024; 10(15):e35509.

PMID: 39170467 PMC: 11336728. DOI: 10.1016/j.heliyon.2024.e35509.

A potential mechanism of tumor immune escape: Regulation and application of soluble natural killer group 2 member D ligands (Review).

Huang S, Qin Z, Wang F, Kang Y, Ren B Oncol Rep. 2024; 52(4).

PMID: 39155864 PMC: 11358674. DOI: 10.3892/or.2024.8796.

References

Lopez-Soto A, Folgueras A, Seto E, Gonzalez S . HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene. 2009; 28(25):2370-82. DOI: 10.1038/onc.2009.117. View

Spear P, Barber A, Rynda-Apple A, Sentman C . NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol Cell Biol. 2013; 91(6):435-40. PMC: 3700668. DOI: 10.1038/icb.2013.17. View

Armeanu S, Bitzer M, Lauer U, Venturelli S, Pathil A, Krusch M . Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005; 65(14):6321-9. DOI: 10.1158/0008-5472.CAN-04-4252. View

Groth A, Kloss S, Pogge von Strandmann E, Koehl U, Koch J . Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance. J Innate Immun. 2011; 3(4):344-54. DOI: 10.1159/000327014. View

Koch J, Steinle A, Watzl C, Mandelboim O . Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol. 2013; 34(4):182-91. DOI: 10.1016/j.it.2013.01.003. View

Wu J, Song Y, Bakker A, Bauer S, Spies T, Lanier L . An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 1999; 285(5428):730-2. DOI: 10.1126/science.285.5428.730. View

Zhang T, Lemoi B, Sentman C . Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood. 2005; 106(5):1544-51. PMC: 1895219. DOI: 10.1182/blood-2004-11-4365. View

Fernandez-Messina L, Reyburn H, Vales-Gomez M . Human NKG2D-ligands: cell biology strategies to ensure immune recognition. Front Immunol. 2012; 3:299. PMC: 3457034. DOI: 10.3389/fimmu.2012.00299. View

Textor S, Fiegler N, Arnold A, Porgador A, Hofmann T, Cerwenka A . Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 2011; 71(18):5998-6009. DOI: 10.1158/0008-5472.CAN-10-3211. View

10.

Coudert J, Zimmer J, Tomasello E, Cebecauer M, Colonna M, Vivier E . Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. Blood. 2005; 106(5):1711-7. DOI: 10.1182/blood-2005-03-0918. View

11.

Inagaki A, Ishida T, Yano H, Ishii T, Kusumoto S, Ito A . Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. Int J Cancer. 2009; 125(1):212-21. DOI: 10.1002/ijc.24351. View

12.

Skov S, Pedersen M, Andresen L, Straten P, Woetmann A, Odum N . Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 2005; 65(23):11136-45. DOI: 10.1158/0008-5472.CAN-05-0599. View

13.

Li H, Lakshmikanth T, Garofalo C, Enge M, Spinnler C, Anichini A . Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle. 2011; 10(19):3346-58. DOI: 10.4161/cc.10.19.17630. View

14.

Muller T, Uherek C, Maki G, Chow K, Schimpf A, Klingemann H . Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother. 2007; 57(3):411-23. PMC: 11029838. DOI: 10.1007/s00262-007-0383-3. View

15.

Wu X, Tao Y, Hou J, Meng X, Shi J . Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma. Neoplasia. 2013; 14(12):1178-89. PMC: 3540943. DOI: 10.1593/neo.121236. View

16.

Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen X . Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res. 2009; 15(16):5208-15. DOI: 10.1158/1078-0432.CCR-09-0886. View

17.

Houchins J, Yabe T, McSherry C, Bach F . DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med. 1991; 173(4):1017-20. PMC: 2190798. DOI: 10.1084/jem.173.4.1017. View

18.

Garrity D, Call M, Feng J, Wucherpfennig K . The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci U S A. 2005; 102(21):7641-6. PMC: 1140444. DOI: 10.1073/pnas.0502439102. View

19.

Guerra N, Tan Y, Joncker N, Choy A, Gallardo F, Xiong N . NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008; 28(4):571-80. PMC: 3528789. DOI: 10.1016/j.immuni.2008.02.016. View

20.

Cerwenka A, Lanier L . NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens. 2003; 61(5):335-43. DOI: 10.1034/j.1399-0039.2003.00070.x. View